Literature DB >> 15557051

Botulinum toxin for cerebral palsy; where are we now?

R E Morton1, J Hankinson, J Nicholson.   

Abstract

In this article, the evidence base for botulinum-A treatment acquired in recent years is outlined, and the practicalities involved in providing this service are described. Botulinum-A is relatively new, and possible improvements for the future are considered.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15557051      PMCID： PMC1719754          DOI： 10.1136/adc.2003.044560

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  43 in total

Review 1.  Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review.

Authors:  R N Boyd; R M Hays
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

Review 2.  Therapeutic choices in the locomotor management of the child with cerebral palsy--more luck than judgement?

Authors:  J H Patrick; A P Roberts; G F Cole
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

3.  Long-term safety and efficacy of continuous intrathecal baclofen.

Authors:  William M Campbell; Anne Ferrel; John F McLaughlin; Gerald A Grant; John D Loeser; Catherine Graubert; Kristie Bjornson
Journal:  Dev Med Child Neurol       Date:  2002-10       Impact factor: 5.449

4.  Hip dysplasia in bilateral cerebral palsy: incidence and natural history in children aged 18 months to 5 years.

Authors:  D Scrutton; G Baird; N Smeeton
Journal:  Dev Med Child Neurol       Date:  2001-09       Impact factor: 5.449

5.  Management of hip dislocation with postural management.

Authors:  Teresa Pountney; Anne Mandy; Elizabeth Green; Paul Gard
Journal:  Child Care Health Dev       Date:  2002-03       Impact factor: 2.508

6.  Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome.

Authors:  D Fehlings; M Rang; J Glazier; C Steele
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

7.  The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial.

Authors:  R N Boyd; F Dobson; J Parrott; S Love; J Oates; A Larson; G Burchall; P Chondros; J Carlin; G Nattrass; H K Graham
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

8.  Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications.

Authors:  I Autti-Rämö; A Larsen; A Taimo; L von Wendt
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

9.  The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial.

Authors:  S C Love; J P Valentine; E M Blair; C J Price; J H Cole; P J Chauvel
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

10.  Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy.

Authors:  Frances Polak; Richard Morton; Christopher Ward; W Angus Wallace; Leonard Doderlein; Andrea Siebel
Journal:  Dev Med Child Neurol       Date:  2002-08       Impact factor: 5.449
View more
  1 in total

1.  Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation.

Authors:  Kristie Bjornson; Ross Hays; Cathy Graubert; Robert Price; Francine Won; John F McLaughlin; Morty Cohen
Journal:  Pediatrics       Date:  2007-07       Impact factor: 7.124
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.